argenx stock adds peptide platform in $1.15 billion UNP deal
Published on 11/13/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAcquisition Expands Peptide Strategy
- argenx agreed to acquire all remaining shares of Unnatural Products after more than two years of collaboration and investment.
- Unnatural Products will keep its Santa Cruz team and lead peptide discovery within argenx after closing.
- The transaction is expected to close by the end of 2026, subject to customary conditions.
argenx announced on Monday, November 9, that it had agreed to acquire Unnatural Products, adding a macrocyclic peptide discovery engine to its immunology platform in a transaction valued at up to $1.15 billion. The announcement came from argenx in Amsterdam at 07:00 CET and covers the purchase of all remaining shares in the privately held company.
Under the agreement, argenx will pay $550 million in cash upfront. A further $595 million could become payable through development and regulatory milestones, making the final consideration dependent on the progress of the acquired platform rather than fixed entirely at closing. The boards of both companies have approved the deal.
Peptides Broaden Drug Discovery
Unnatural Products brings expertise in macrocyclic peptides, a class of molecules that can support drug discovery against targets that are difficult to address with conventional approaches. Its platform combines parallel experimentation with machine learning and is intended to broaden the ways argenx can pursue novel biology.
argenx said the acquisition could support oral or long-acting medicines for people living with serious immune-mediated diseases. The strategy complements the company's antibody engineering capabilities and extends a collaboration that has lasted more than two years.
Chief Executive Officer Karen Massey described the peptide capabilities as highly complementary to argenx's antibody engineering. She said the company was investing with discipline as it builds its next chapter in immunology. Unnatural Products CEO and co-founder Cameron Pye said argenx could accelerate the platform's development and help bring new therapies to patients.
Santa Cruz Becomes Peptide Hub
Following completion, Unnatural Products will continue operating from its Santa Cruz, California site, which will become argenx's home for peptide discovery. The existing team and leadership will continue to lead discovery work within a strategic framework agreed with argenx, while argenx contributes clinical development and commercialization capabilities.
The structure leaves investors with two important execution questions: whether the transaction closes on schedule and whether the acquired research produces development and regulatory milestones. The $550 million upfront payment is committed under the agreement, while the additional consideration depends on future progress. The acquisition is expected to close by the end of 2026, subject to customary closing conditions.
For the share-price context, argenx stock traded at 893.60 euros on Lang & Schwarz at 10:03 CET on Friday, November 13. The quote provides a current trading reference, while the acquisition remains an operating and pipeline event rather than a completed transaction.
The transaction details, strategic rationale and management comments are set out in the argenx announcement.
argenx stock at a glance
- Company: argenx SE
- ISIN: NL0010832176
- Ticker: ARGX
- Trading venue: Lang & Schwarz
- Price: 893.60 euros at 10:03 CET on Friday, November 13, 2026
- Transaction: Unnatural Products acquisition expected to close by year-end 2026
Investors can follow the broader European market backdrop through current market reports.
More news and analyses on argenx stock are available on the company topic page.
